Arbutus Biopharma appoints Tram Tran, M.D. to board of directors

Arbutus Biopharma Corp

Board expanded to nine members; Dr. Tran appointed effective November 9, 2021.
Annual cash retainer of $40,000 plus option for 44,000 shares at $3.50, vesting over 3 years.
Dr. Tran is CMO at Glympse and former Gilead VP, with expertise in liver diseases and HBV.
Appointment runs until the 2022 annual general meeting, subject to continued board service.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tram Tran

Director

ABUS · Arbutus Biopharma Corp

Effective: 2021-11-09
Filed: November 12, 2021, 6:59 PM ET

On November 9, 2021, the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) (a) increased the size of the Board by one member such that the Board will thereafter consist of nine directors and (b) appointed Tram Tran, M.D. to the Board, to serve until the Company’s 2022 annual general meeting of shareholders and until her successor is duly appointed and qualified, or until her earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tram Tran was appointed as Director at Arbutus Biopharma Corp.

Action: appointed
Role: Director

Exact text from the filing

On November 9, 2021, the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) (a) increased the size of the Board by one member such that the Board will thereafter consist of nine directors and (b) appointed Tram Tran, M.D. to the Board, to serve until the Company’s 2022 annual general meeting of shareholders and until her successor is duly appointed and qualified, or until her earlier death, resignation or removal.

View on SEC.gov

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-21-007863

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.